`_______________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`SAMSUNG BIOEPIS CO., LTD.
`Petitioner,
`
`v.
`REGENERON PHARMACEUTICALS, INC.
`Patent Owner.
`
`Patent No. 11,253,572
`
`_______________
`Inter Partes Review No. IPR2023-00884
`____________________________________________________________
`
`DECLARATION OF DARALYN J. DURIE IN SUPPORT OF
`MOTION FOR ADMISSION PRO HAC VICE
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2061 Page 1
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`
`
`
`
`I, Daralyn J. Durie, declare as follows:
`
`1.
`
`I am an attorney licensed to practice law in the state of California and
`
`am admitted to practice before the United States Court of Appeals for the Federal
`
`Circuit. I am also admitted to practice before the United States Court of Appeals
`
`for the 1st Circuit, the United States Court of Appeals for the 3rd Circuit, the
`
`United States Court of Appeals for the 8th Circuit, the United States Court of
`
`Appeals for the 9th Circuit, the United States District Courts in the Northern,
`
`Central, Eastern, and Southern Districts of California, and the Eastern District of
`
`Texas, among other courts.
`
`2.
`
`I am a member in good standing in all jurisdictions where I have been
`
`admitted to practice.
`
`3.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`4.
`
`I have never had an application denied for admission before any court
`
`or administrative body.
`
`5.
`
`I have never had any sanctions or contempt citations imposed by any
`
`court or administrative body.
`
`6.
`
`I have read and agree to comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in 37 C.F.R. part 42.
`
`7.
`
`I affirm my agreement before the USPTO to be subject to the USPTO
`
`
`
`1
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2061 Page 2
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`
`
`
`
`Rules of Professional Conduct 37 C.F.R. §§ 11.101 et seq. and disciplinary
`
`jurisdiction under 37 C.F.R. § 11.19(a).
`
`8.
`
`I have applied to appear pro hac vice in the following proceedings
`
`before the USPTO in the last three (3) years:
`
`a. Celltrion Inc. v. Regeneron Pharmaceuticals Inc., IPR2023-00462
`
`(pro hac vice granted; pending);
`
`b. Samsung Bioepis Co., LTD v. Regeneron Pharmaceuticals Inc.,
`
`IPR2023-00739 (pro hac vice pending);
`
`c. Mylan Pharmaceuticals, Inc. v. Regeneron Pharmaceuticals Inc.,
`
`IPR2022-01225 (consolidated with Celltrion, Inc. v. Regeneron
`
`Pharmaceuticals, Inc., IPR2023-00532) (pro hac vice granted);
`
`d. Mylan Pharmaceuticals, Inc. Celltrion Inc., and Samsung Bioepis
`
`Co., Ltd. v. Regeneron Pharmaceuticals Inc., IPR2022-01226
`
`(consolidated with Celltrion, Inc. v. Regeneron Pharmaceuticals,
`
`Inc., IPR2023-00533 and Samsung Bioepis Co., Ltd. v. Regeneron
`
`Pharmaceuticals, Inc., IPR2023-00566) (pro hac vice granted);
`
`e. Dropworks, Inc. v. Lawrence Livermore National Security LLC,
`
`IPR2021-00218 (pro hac vice granted; terminated);
`
`f. Dropworks, Inc. v. Lawrence Livermore National Security LLC,
`
`
`
`2
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2061 Page 3
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`
`
`
`
`IPR2021-00302 (pro hac vice granted; terminated);
`
`g. Dropworks, Inc. v. President and Fellows of Harvard College,
`
`IPR2021-00828 (pro hac vice granted; terminated).
`
`9.
`
`I have been a partner at the law firm of Morrison & Foerster LLP
`
`since I joined the firm on January 1, 2023. I was previously a partner at the law
`
`firm of Durie Tangri LLP from 2009 through December 31, 2022. I have
`
`worked on patent litigation matters for over 20 years. I have handled patent
`
`cases relating to biotechnology for more than 16 years, and in this time I have
`
`handled many patent cases relating to methods of treatment using antibodies.
`
`10.
`
`I am familiar with the subject matter at issue in this proceeding. I
`
`have been engaged by the Patent Owner to represent the Patent Owner before the
`
`Board in this proceeding. I have undertaken the study of inter alia the ’572
`
`Patent, the Petition for Inter Partes Review, and the art cited in the Petition. I
`
`am also familiar with the co-pending litigations identified by the Petitioner in the
`
`Petition for Inter Partes Review, Paper 2 at 6. I have represented Patent Owner
`
`in patent matters relating to Eylea® since September 2022. I have acquired a
`
`substantial understanding of the underlying legal and technological issues at
`
`stake in these proceedings.
`
`
`
`
`
`3
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2061 Page 4
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code and that such willful false
`
`statements may jeopardize the validity of U.S. Patent No. 11,253,572.
`
`Dated: December 20, 2023
`
`By: /Daralyn J. Durie/
`Daralyn J. Durie
`MORRISON & FOERSTER LLP
`425 Market Street
`San Francisco, California 94105
`Tel: (415) 268-6055
`
`4
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2061 Page 5
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`